Latest Breaking News On - Sepracor inc - Page 4 : comparemela.com

Biosketch Bill Yelle has over 30 years of experience in the biopharmaceutical industry, ranging from large pharma to early stage, venture-backed companies. He currently serves as an Entrepreneur in Residence at Partners Innovation Fund (PIF) as well as an Adjunct Faculty Member at The Manning School of Business at UMass Lowell.  Before joining PIF, Bill was Executive Chairman of Envisia Therapeutics, as well as an advisor to several entrepreneurial startups. Prior to Envisia, Bill served as CEO of Aldea Pharmaceuticals, where he successfully completed a Series B raise and brought two programs into the clinic. Prior to Aldea, he was Senior Vice President of Corporate Development and Licensing for Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.), where he was responsible for the consummation of over 30 material transactions, the most notable being the company’s sale to Dainippon Sumitomo Pharma for $2.6 billion in 2009. 

Dainippon sumitomo pharmaUmass lowellLicensing for sunovion pharmaceuticals incAldea pharmaceuticalsEntrepreneur in residence at partners innovation fundSepracor incColumbia universityManning school of businessCorporate developmentUniversity of california at berkeleyJackm wilson centerUniversity of massachusetts lowellPfizer us pharmaceuticals groupPartners innovation fundAdjunct faculty memberManning school